ASCO GU recap: Insights on 5 key trials

In this video, Urology Times® highlights 5 interviews on key trial data presented at the 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco, California.

Specifically, we showcase:

• Fred Saad, MD, FRCS: “Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial”
• Nima Sharifi, MD: “HSD3B1 and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial”
• Pooja Ghatalia, MD: “A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)”
• Gopa Iyer, MD: “EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)”
• Laurence Albiges, MD, PhD: “Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313”

These 5 videos represent a snapshot of all of the data that were covered at this year’s meeting! You can view our full ASCO GU coverage here.